LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

Back in at a Christmas bargain price.I sound like a trader lol.

Bugger!

from Mail online ..........

22 December 2009 - The secret to a healthy life? Try tomato seeds -- By Sean Poulter -

A natural ingredient found in tomato seeds has been identified by British scientists as a key component to a long and healthy life.

The gel prevents the blood from becoming sticky and clotting and so is being promoted as a natural alternative to aspirin.
It was discovered by food researchers investigating the benefits of a Mediterranean diet.

Patented as Fruitflow, it is already being used in one fruit juice product and is now expected to be added to dairy drinks, spreads and other foods.
EU health watchdogs have accepted thatthe ingredient does improve blood flow and have approved the use of such claims on packaging.
Fruitflow was discovered in 1999 by Professor Asim Dutta-Roy at the Rowett Institute in Aberdeen.

It is derived from the gel around tomato seeds. Clinical trials have shown it can help maintain a healthy blood circulation by preventing the clumping of blood platelets which can lead to clots.

Both Fruitflow and aspirin work by changing the characteristics of platelets, which are tiny cells in the blood. Normally they are smooth, but inflammation in the blood vessels - linked to smoking, high cholesterol and stress - causes them to become spiky and so stick together, forming clots.

Aspirin strongly blocks one set of signals that causes this to happen. Fruitflow more gently damps down three others, enough to reduce the risk of clotting.

Currently, millions of older people take small doses of aspirin daily to improve blood flow.

However this can have unwelcome side effects such as bleeding in the stomach and the creation of ulcers. Professor-Dutta-Roy said: 'To date, no side effects have been demonstrated during the development of Fruitflow.'
Research shows that a smoother blood flow can be seen within three hours of taking Fruitflow and the results can last up to 18 hours, making it ideal for daily consumption.

The gel, which is colourless and tasteless, is extracted from tomato seeds and can then be added to a range of foods without changing their characteristics.

It is currently added to Sirco, a range of 100 per cent pure fruit juices available from Waitrose, Ocado and some health food shops.

What one gets of the Open Offer ?

The full amount, but if applied for extra then 1.9 times the shares subcribed for. Although only 56.72% basic pro rata entitlement were being applied, Investors asking for extra amounted close to 10 times the shares being offered ...........


Result of Open Offer

The Board of Provexis is pleased to announce the result of the Open Offer which
closed at 11.00a.m. on Monday 21 December. The Open Offer has raised
GBP2.1million and accordingly 85,211,664 Offer Shares have been issued at a
price of 2.5p each.

The number of Offer Shares applied for by Qualifying Shareholders under their
basic pro rata entitlement was 48,335,151 Offer Shares, representing 56.72 per
cent. of the total number of Offer Shares available. All applications by
Qualifying Shareholders for their basic pro rata Open Offer Entitlement have
been satisfied in full.

The number of Offer Shares applied for by Qualifying Shareholders under the
Excess Application Facility amounted to 336,326,065 Offer Shares. The Company
has scaled back excess applications on a pro rata basis in proportion to the
total number of Excess Shares applied for under the Excess Application Facility.
The Company is therefore issuing 36,876,513 Offer Shares, under the Excess
Application Facility.

I will see that buggerand raise a yippee.what a difference a few hours make?

Has anyody had these shares credited to their account?

I'm with Halifax and they have been feeding the bull about not receiving any instructions from the company about how many excess shares I am entitled to!

It would be nice to get that money back in the account and do some trading.

yes - IG show my full amount

what excess amount did you receive relative to what u applied for.

I think it's a tenth but I haven't received them yet.

Off to the sunshine state now for three weeks. Merry Christmas one and all and a prosperrous new year.

enjoy Chinatown in SF!

PXS starting to wake up once more .... for sure an imminent RNS re licensing deal or similar is hoped for, but just perhaps it is indeed (realtively!) about to appear

Was that 1,000,000, seen after hours, late reported deal @ 8.25 a buy or a sell I wonder, and from when? It would be nice if it was a director buying, nothing reported though.

Don't forget to have a glass of Sirco before you next board a plane!

http://www.cisionwire.com/ccd-healthcare-pr/fruit-juice-drink-proven-to-reduce-dvt-travel-fears

have one every day kim.... very nice too.

Snap! Both me and the other arf drink it every morning. Both flavours really nice. Plus Holland and Barret currently doing buy one get one half. Come on lets be having the Aspirin results!

Yes, it is a nice drink, let's hope it turns into a nice(r) share to hold!

thanks for telling us that blanche, didn't realise, will stock up as it has an excellent use by date.

how much do you pay? are's here is 1.99/ltr

who the f* cares!? ...... it's some progress on licencing deals or similar since the last rns that's of any importance